Results 241 to 250 of about 106,594 (302)

High density lipoproteins, disease severity and clinical outcomes in patients with idiopathic pulmonary fibrosis. [PDF]

Respir Res
Podolanczuk AJ, Mulder H, Kim JS, Neely ML, Kaner RJ, Todd JL.   +5 more
europepmc   +1 more source

Outcomes of Clostridium difficile Infection in Patients With Idiopathic Pulmonary Fibrosis: Analysis of the Nationwide Inpatient Sample, 2016–2020

JGH Open, Volume 10, Issue 5, May 2026.
ABSTRACT Background Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with poor prognosis. Patients with IPF are frequently exposed to risk factors for Clostridium difficile infection (CDI), such as advanced age, antibiotic use, and gastric acid suppression.
Chun Ho Szeto, Gloria Erazo Montalvan, Chung Yin Tai, Edgar Luna Landa, Godfrey Tabowei, Raymond Wadie, Raghavendra Sanivarapu   +6 more
wiley   +1 more source

Idiopathic pulmonary fibrosis from a multiscale mechanobiology perspective: Mechanisms and future therapeutic prospects. [PDF]

iScience
Xia T, Wang X, Yang Z, Zhao R.
europepmc   +1 more source

Targeting Tumor Stroma: Current Challenges and Future Directions

MedComm, Volume 7, Issue 5, May 2026.
Figure 1. Mechanism of ECM reprogramming. Cancer‐associated fibroblasts (CAFs), cancer‐associated macrophages (CAMs), and other mesenchymal cells alter the ECM composition and increase its stiffness by depositing matrix components such as collagen and hyaluronic acid, and secreting cross‐linking agents like lysyl oxidase homolog 2 (LOXL2).
Siwei Wang, Haofan Hu, Weifeng Zeng, Lu Qin, Xiaoping Chen, Zhibin Liao, Furong Liu, Zhanguo Zhang   +7 more
wiley   +1 more source

Correction: Use of supplemental oxygen therapy in idiopathic pulmonary fibrosis: an observational real-life study in 16 003 patients. [PDF]

BMJ Open Respir Res
europepmc   +1 more source

Comparison of the Efficacy of Pirfenidone and Nintedanib in the Treatment of Patients with Idiopathic Pulmonary Fibrosis-A Single-Center Experience. [PDF]

Medicina (Kaunas)
Trboljevac N, Dimic-Janjic S, Kontic M, Omcikus M, Ilic B, Markovic F, Postic A, Isovic L, Stjepanovic M, Nenezic D.   +9 more
europepmc   +1 more source

Efferocytosis: Signaling Pathways and New Therapeutic Strategies for Diseases

MedComm, Volume 7, Issue 5, May 2026.
1. Efferocytosis coordinates molecular signaling and metabolic reprogramming to resolve inflammation. 2. Efferocytosis dysfunction underlies four conserved pathological hallmarks across diseases. 3. Therapeutic strategies targeting efferocytosis should be context‐dependent: enhance or inhibit based on disease type. ABSTRACT Efferocytosis—the phagocytic
Lei Wang, Jingjing Ge, Zehua Wang, Yihua Fang, Yongxu Jia, Ruyue Zhang, Yanru Qin   +6 more
wiley   +1 more source

Idiopathic Pulmonary Fibrosis: Cellular Heterogeneity, Mechanisms, and Therapeutic Implications. [PDF]

MedComm (2020)
Zuo L, Liu Q, Ye D, Fan J, Wu L.
europepmc   +1 more source

Advances in the research and application of stem cell therapies for idiopathic pulmonary fibrosis. [PDF]

Am J Clin Exp Immunol
Xu L, Hou X, Zhou X, Jiang M.
europepmc   +1 more source

Triple Calamity in a Smoker: Idiopathic Pulmonary Fibrosis, Chronic Pulmonary Aspergillosis, and Lung Adenocarcinoma. [PDF]

Cureus
Sahoo S, Patro M, Mohapatra PR, Sable M, Hallur VK, Panigrahi MK.   +5 more
europepmc   +1 more source